Gufic Biosciences jumps as board approves amalgamation of Gufic Lifesciences

Gufic Biosciences surged 4.46% to Rs 70.30 at 11:58 IST on BSE after the company announced that its board approved the amalgamation of Gufic Lifesciences with the company.

The announcement was made after market hours on Monday, 3 April 2017.

Meanwhile, the S&P Sensex was up 23.82 points, or 0.08% at 29,934.04. The S&P BSE Small-cap index was up 152.47 points, or 1.04% at 14,772.70.

On the BSE, 92,000 shares were traded on the counter so far as against the average daily volumes of 1.24 lakh shares in the past one quarter. The stock had hit a high of Rs 70.95 and a low of Rs 67.70 so far during the day.

The stock had hit a record high of Rs 72.50 on 28 March 2017 and a 52-week low of Rs 33.30 on 29 September 2016. The stock had outperformed the market over the past one month till 3 April 2017, advancing 20.07% compared with the Sensex's 3.74% rise. The scrip had also outperformed the market over the past one quarter advancing 18.17% as against the Sensex's 12.26% rise.

The small-cap company has equity capital of Rs 7.74 crore. Face value per share is Rs 1.

Gufic Biosciences announced that its board at a meeting held on Monday, 3 April 2017, approved the amalgamation of Gufic Lifesciences with the company. The share exchange ratio shall be approved by the board of directors based on the valuation report of an expert to be obtained in due course and the effective date of amalgamation shall also be decided by the board.

Gufic Biosciences' net profit rose 28.1% to Rs 3.10 crore on 15.9% increase in net sales to Rs 64.97 crore in Q3 December 2016 over Q3 December 2015.

Gufic Biosciences is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Powered by Capital Market - Live News